Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Report 2026

Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Overview

• Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment market size has reached to $0.6 billion in 2025 • Expected to grow to $0.93 billion in 2030 at a compound annual growth rate (CAGR) of 9.2% • Growth Driver: Increase In Healthcare Expenditure Driving The Growth Of The Market Due To Advancements In Medical Technology And Research Funding • Market Trend: Advancements In Monoclonal Antibody Therapies Driving Innovation In Warm Autoimmune Hemolytic Anemia Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

Warm autoimmune hemolytic anemia (WAIHA) treatment focuses on managing the immune system's abnormal response, which targets and destroys red blood cells at normal body temperature. The primary goal is to reduce or halt this immune-mediated destruction, restore healthy red blood cell levels, and alleviate symptoms such as fatigue, shortness of breath, and pallor. The main types of warm autoimmune hemolytic anemia (WAIHA) treatment are corticosteroids, monoclonal antibodies, intravenous immunoglobulin (IVIG), blood transfusions, and splenectomy. Corticosteroids are anti-inflammatory drugs used to suppress the immune system and reduce inflammation. It can be administered through oral, intravenous, and subcutaneous routes for children, adults, and geriatric patients. It is used for primary autoimmune disorders, secondary autoimmune disorders, and genetic predisposition and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Growth Forecast?

The warm autoimmune hemolytic anemia (waiha) treatment market size is expected to see strong growth in the next few years. It will grow to $0.93 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to biologic drug innovation, improved autoimmune diagnostics, expansion of precision medicine, growing geriatric population, specialty hematology care growth. Major trends in the forecast period include increased use of monoclonal antibody therapies, rising adoption of steroid-sparing treatments, expansion of personalized autoimmune therapies, growing role of ivig in acute management, improved diagnostic and monitoring protocols.

Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Segmentation

1) By Treatment Type: Corticosteroids, Monoclonal Antibodies, Intravenous Immunoglobulin (IVIG), Blood Transfusions, Splenectomy 2) By Route Of Administration: Oral, Intravenous, Subcutaneous 3) By Patient Demographics: Children, Adults, Geriatric 4) By Therapeutic Area: Primary Autoimmune Disorders, Secondary Autoimmune Disorders, Genetic Predisposition 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone 2) By Monoclonal Antibodies: Rituximab, Sutimlimab, Bortezomib 3) By Intravenous Immunoglobulin: Standard IVIG, High-Dose IVIG Therapy, Pooled Plasma-Derived Immunoglobulins 4) By Blood Transfusions: Leukoreduced RBC Transfusions, Emergency Transfusions, Phenotypically Matched RBC Transfusions 5) By Splenectomy: Laparoscopic Splenectomy, Prophylactic Treatments Post-Splenectomy, Open Splenectomy

What Is The Driver Of The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

The increasing healthcare expenditure is projected to fuel the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment market going forward. Healthcare expenditure refers to the total amount of resources spent on health services, including prevention, diagnosis, treatment, and management of diseases, by individuals, governments, and organizations. Advancements in medical technology are driving up healthcare expenditure, as newer diagnostic tools and treatments often come with higher costs for development, implementation, and ongoing patient care. Healthcare expenditure supports warm autoimmune hemolytic anemia (WAIHA) treatment by funding research, providing access to advanced diagnostic tools, and ensuring the availability of specialized therapies that help manage and control the disease. For instance, in May 2024, according to the Office for National Statistics, a UK-based government agency, in real terms, long-term health and social care expenditures increased by 2.8% in 2022, but overall healthcare spending increased by 5.6% in 2023. Therefore, the increasing healthcare expenditure is driving the growth of the warm autoimmune hemolytic anemia (WAIHA) treatment industry.

Key Players In The Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

Major companies operating in the warm autoimmune hemolytic anemia (waiha) treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte Corporation, Mallinckrodt Pharmaceuticals, Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, ADMA Biologics Inc., Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc.

Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Trends and Insights

Major companies operating in the warm autoimmune hemolytic anemia (WAIHA) treatment market are focusing on developing innovative solutions, such as monoclonal antibodies, to address the unmet clinical needs and improve patient outcomes. Monoclonal antibodies are lab-engineered proteins that target specific immune cells or pathways to reduce the destruction of red blood cells in warm autoimmune hemolytic anemia. For instance, in July 2023, IASO Biotechnology, a China-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval for IASO-782 Injection for use in clinical studies for autoimmune hematological conditions in the United States, such as warm autoimmune hemolytic anemia (WAIHA) and primary immune thrombocytopenia (ITP). Targeting CD19, this fully human monoclonal antibody has Fc mutations to increase ADCC activity while maintaining other Fc functions. It selectively depletes CD19+ B cells, plasma blasts, and some plasma cells, which are responsible for producing auto-reactive antibodies. Due to its distinct mechanism, IASO-782 may be used to treat autoimmune illnesses that are caused by pathogenic B and plasma cells, such as ITP and AIHA.

What Are Latest Mergers And Acquisitions In The Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

In September 2023, Zenas BioPharma Inc., a US-based biotechnology company, collaborated with Bristol Myers Squibb for the creation and distribution of the obexelimab antibody, which is used to treat autoimmune diseases. With this collaboration, the aim is to develop and commercialize effective new treatments for autoimmune diseases in key Asian-Pacific markets, addressing unmet medical needs and improving patient outcomes. Bristol Myers Squibb is a US-based pharmaceutical company specializing in warm autoimmune hemolytic anemia (WAIHA) treatment.

Regional Insights

North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

The warm autoimmune hemolytic anemia (WAIHA) treatment market consists of revenues earned by entities by providing services such as diagnostic testing services, immune system monitoring, personalized treatment planning and care coordination services. The market value includes the value of related goods sold by the service provider or included within the service offering. The warm autoimmune hemolytic anemia (WAIHA) treatment market also includes sales of diagnostic kits, immunomodulatory agents, hematology analyzers and red blood cell monitoring tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Report 2026?

The warm autoimmune hemolytic anemia (waiha) treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the warm autoimmune hemolytic anemia (waiha) treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.